文献速递心律失常

房颤合并阿尔茨海默病患者口服抗凝药与认知及临床结局的瑞典全国研究

Oral anticoagulants, cognition, and clinical outcomes in atrial fibrillation and Alzheimer's disease: a Swedish nationwide study.
PubMed 文献 · Eur Heart J · 2026-08-12

这项瑞典全国性研究纳入7308例房颤合并阿尔茨海默病(AD)患者,比较非使用、华法林与NOACs三组的认知轨迹和临床结局。结果显示NOACs使用者的MMSE年下降幅度显著小于非使用者和华法林使用者,且较非使用者显著降低死亡、缺血性卒中/体循环栓塞和骨折风险,未增加大出血风险。

要点

  • 房颤合并AD患者使用NOACs较不使用或华法林认知下降更慢
  • NOACs较不使用显著降低死亡、缺血性卒中/体循环栓塞和骨折风险
  • NOACs较大出血风险未增加,而华法林大出血风险显著升高

核心结论

  • NOAC使用与房颤合并AD患者认知下降更慢以及较华法林或不抗凝更优的有效性和安全性相关

研究设计与样本

  • 基于瑞典认知/痴呆障碍登记库的全国性观察性研究
  • 采用逆概率加权平衡协变量,混合效应模型评估MMSE认知变化,Cox模型评估临床结局

主要发现

  • NOAC使用者与非使用者相比MMSE评分差异为0.23分/年(95%CI 0.11-0.36),认知下降显著更慢
  • NOAC使用者与华法林使用者相比MMSE评分差异为0.21分/年(95%CI 0.10-0.33),认知下降显著更慢
  • 与非使用抗凝药相比,NOAC使用显著降低死亡率(HR 0.81;95%CI 0.72-0.91)
  • 与非使用抗凝药相比,NOAC使用显著降低缺血性卒中/体循环栓塞(HR 0.66;95%CI 0.53-0.82)和骨折(HR 0.79;95%CI 0.64-0.97)
  • 华法林使用与非使用相比显著降低死亡率(HR 0.88;95%CI 0.80-0.97),但大出血风险升高(HR 1.31;95%CI 1.09-1.56)

关键数值与推荐

  • 研究人群:7308例,其中3341例非使用者、2277例华法林使用者、1690例NOAC使用者
  • NOAC与非使用相比大出血HR 1.05(95%CI 0.84-1.32),未显示风险增加
  • NOAC与华法林相比缺血性卒中/体循环栓塞HR 0.78(95%CI 0.62-0.98),大出血HR 0.80(95%CI 0.64-1.01)

临床怎么用

  • 房颤合并AD患者可优先考虑NOACs抗凝以兼顾认知保护和临床结局
  • 使用华法林者需警惕大出血风险升高

局限性

  • 观察性研究无法完全排除残余混杂
  • MMSE作为认知评估工具对轻度变化敏感性有限

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Use of non-vitamin K oral anticoagulants (NOACs) is associated with reduced dementia risk in patients with atrial fibrillation (AF), but their impact on cognitive function and clinical outcomes in AF patients with Alzheimer's disease (AD) remains unclear. METHODS: Based on the Swedish Registry for Cognitive/Dementia Disorders, individuals with incident AD during May 2007-December 2020 and pre-existing AF were identified. Anticoagulant use at baseline was categorized as non-use, warfarin, or NOACs. Inverse probability of treatment weighting was employed to balance covariates. Mixed-effects models were used to assess the association between anticoagulant use and cognitive decline measured by the Mini-Mental State Examination (MMSE). Cox proportional hazards models were used to examine risks of all-cause mortality, ischaemic stroke/systemic embolism, major bleeding, and fracture. RESULTS: Among 7308 eligible individuals (3341 non-users, 2277 warfarin users, and 1690 NOAC users), NOAC users exhibited significantly slower cognitive decline compared to non-users (difference in MMSE scores β = 0.23 points/year, 95% confidence interval [CI] 0.11-0.36) and warfarin users (β = 0.21 points/year, 95% CI 0.10-0.33). Compared to non-use of anticoagulants, NOAC use was associated with significantly lower rates of mortality (hazard ratio [HR] 0.81; 95% CI 0.72-0.91), ischaemic stroke/systemic embolism (HR 0.66; 95% CI 0.53-0.82), and fracture (HR 0.79; 95% CI 0.64-0.97), without an increased rate of major bleeding (HR 1.05; 95% CI 0.84-1.32); in contrast, warfarin use was associated with significantly lower rates of mortality (HR 0.88; 95% CI 0.80-0.97) and ischaemic stroke/systemic embolism (HR 0.85; 95% CI 0.72-1.00), but a higher rate of major bleeding (HR 1.31; 95% CI 1.09-1.56). Compared to warfarin, NOAC use was associated with lower rates of ischaemic stroke/systemic embolism (HR 0.78; 95% CI 0.62-0.98) and major bleeding (HR 0.80; 95% CI 0.64-1.01), and non-significant reductions in mortality and fracture. CONCLUSIONS: In patients with AF and AD, NOAC use was associated with modestly slower cognitive decline and more favourable effectiveness and safety profiles, compared to warfarin or no anticoagulation.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Zhu, Xu, Garcia-Ptacek, et al. Oral anticoagulants, cognition, and clinical outcomes in atrial fibrillation and Alzheimer's disease: a Swedish nationwide study. Eur Heart J. 2026. PMID: 42583837. doi:10.1093/eurheartj/ehag584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。